June 17, 2020 - The Covid-19 has wreaked havoc in the stock market when it originally burst. However, Wall Street is on a significant bullish rally these days: The S&P 500 has erased all losses since the beginning of 2020, and the NASDAQ is at an all-time high. According to TradingTecks' expert analysts, Though the market has surged these past months, some companies in the pharma sector that work on treatments or tests for COVID-19 are still undervalued. TradingTeck experts have found several of these stocks and recommend them.

Opko
According to TradingTeck, one stock you should be looking at right now is the Israeli Opko stock. The NASDAQ traded company has received FDA approval for stage 2 experiment in RAYALDEE, extended-release capsule meant for treating symptomatic cases of Coronavirus. It's worth noting that Opk has more than doubled its value, mainly due to manufacturing tests for Coronavirus.

Moderna
Moderna is currently working on a promising vaccine for Coronavirus. As for now, Moderna is probably the leading company in the world right now that is working on a COVID-19 Vaccine. The U.S. administration has selected five companies that will receive federal funding for generating a cure, and Moderna belongs with this exclusive bunch. Modernas' Vaccine is based on an innovative genetic Technology, named messenger RNA (mRNA), which will make the body's DNA to generate specific protein cells, that will help the body heal from the virus. According to TradingTeck, even though this is a relatively early stage (it will be a year and a half to complete clinical trials), manufacturing the drug is easy and cheap. If successful, the stock is expected to rise significantly.

Novavax
On May 12th, Novavax has increased by over 70% due to funding received by the Coalition for Epidemic Preparedness Innovations (CEPI). According to TradingTeck, though Novavax hasn't received federal funding, the company is showing relative progress in finding a cure. Novavax even landed a U.S. Department of Defense contract to supply its Vaccine for the military. According to TradingTeck, The company has another growth engine in its sleeve: nanoparticle-based flu vaccine NanoFlu, that if approved, could reach annual sales of $1.7 billion. With CEPI funding and a U.S. Department of Defense contract, this company is in a good position for growth.

Media Contact
TradingTeck